



TOSOH

TOSOH BIOSCIENCE

Tosoh Bioscience Launches the ST AIA-PACK BNP Assay for use on Tosoh System Analyzers

South San Francisco, CA – June 2022 – The Tosoh ST AIA-PACK BNP assay is designed for IN VITRO DIAGNOSTIC USE ONLY for the quantitative measurement of BNP in human (K2EDTA) plasma on Tosoh AIA System Analyzers. BNP is used as an aid in the diagnosis of heart failure (HF) in patients presenting to the emergency department (ED) with clinical suspicion of new onset HF, acutely decompensated or exacerbated HF.

Utilizing Tosoh's unit dose test cup reagent technology, ST AIA-PACK BNP has an assay time of approximately 18 minutes. Single, unitized test cups require no pre-mixing, no pre-measuring and no on-board refrigeration. Dry reagent format ensures 90-day calibration stability for minimal waste and cost-effective testing. Test cups are bar-coded for easy identification and inventory management. The ST AIA-PACK BNP assay has an assay range of 4 to 2000 pg/mL and is free from Biotin interference.

It is estimated that 6.2 million U.S. adults (≥ 20 years of age) have heart failure (HF). This represents an increase from previous estimates of 5.7 million between the years 2009-2012. The prevalence of HF is projected to increase by 46% from 2021 to 2030, affecting > 8.0 million adults (≥ 18 years of age) by the year 2030. Heart Failure is a condition in which the heart is weakened and cannot supply a sufficient amount of blood to cells within the body. While this condition can occur at any age it is more prevalent in older adults. The symptoms of HF include fatigue, shortness of breath, coughing and fluid retention. Since the symptoms of HF are vague and non-specific, an accurate and timely diagnosis is required.

B-type natriuretic peptide (BNP) is a cardiac hormone consisting of 32 amino acid residues. The structure is similar to another cardiac hormone, atrial natriuretic peptide (ANP). These peptides are known to have diuretic, natriuretic, and vasodilatory effects as well as suppress sympathetic nervous and renin-angiotensin-aldosterone systems.

The release of BNP from the heart is increased in response to mechanical or neurohormonal stimulation of the heart, leading to the rise of the BNP level in blood. Multiple studies have demonstrated that increasing levels of circulating BNP are found in patients that are in the early stages of HF. As HF advances, the levels of BNP also rise. Further, elevated levels of BNP correlate with left ventricular dysfunction and with the New York Heart Association class of diagnosis.

The Tosoh ST AIA-PACK BNP assay offers a non-invasive method to accurately measure BNP levels in a blood sample for assessing patients for HF. The compact AIA-360 is ideal for emergency rooms and can be used with other cardiac markers like Troponin I, CKMB and Myoglobin.

Reference: ST AIA-PACK BNP Analyte Application Manual.

ABOUT TOSOH BIOSCIENCE, INC.:

Tosoh Bioscience Inc (TBI) provides highly sophisticated diagnostic systems for immunoassay and HPLC testing to doctor's offices, hospitals and reference laboratories throughout the Americas. Based in South San Francisco, CA, TBI is a U.S. subsidiary of Tosoh Corporation which is headquartered in Tokyo, Japan. TBI is part of Tosoh Corporation's Bioscience Division.

Contact: Karen Wrona
AIA Product Manager
Email: karen.wrona@tosoh.com

TOSOH BIOSCIENCE, INC.

6000 Shoreline Court, Suite 101
South San Francisco, CA 94080 USA
Tel: +1 (800) 248-6764 Fax: +1 (650) 615-0415
Email: info.diag.am@tosoh.com Website: www.tosohbioscience.us